Drug Manufacturing

Mirai Bio and Thermo Fisher to advance genetic medicine development

Mirai Bio has entered into a strategic partnership with Thermo Fisher Scientific to accelerate the development of genetic medicines.

Canadian research initiative secures grant for paediatric brain cancer

The University of Calgary and Alberta Children’s Hospital have secured C$68,000 ($48,694) from Brain Cancer Canada for a research initiative spearhead by Dr Patrick Sipila and Dr Aru Narendran, aimed at improving outcomes for children with aggressive brain cancers.

AbbVie and ADARx to develop siRNA therapeutics for multiple disease areas

AbbVie and ADARx Pharmaceuticals have announced a partnership and licence option deal for developing small interfering ribonucleic acid (siRNA) therapeutics targeting various disease areas such as immunology, oncology, and neuroscience.

FDA to review Regenxbio’s gene therapy BLA for Hunter syndrome

Regenxbio has announced the acceptance of its biologics license application (BLA) by the US Food and Drug Administration (FDA) of its gene therapy clemidsogene lanparvovec (RGX-121) for review to potentially treat Mucopolysaccharidosis II (MPS II), also referred as Hunter syndrome.

InnoCare’s Mesutoclax obtains breakthrough therapy designation in China

InnoCare’s B-cell lymphoma-2 (BCL2) inhibitor, Mesutoclax (ICP-248), has secured breakthrough therapy designation (BTD) from the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE).

Sirius secures $50m to advance siRNA therapeutics for cardiometabolic disorders

Sirius Therapeutics has secured around $50m in a Series B2 funding round for the clinical development of small interfering RNA (siRNA) therapeutics targeting cardiometabolic disorders.

MIRA secures board approval to buy SKNY Pharmaceuticals

US-based firm MIRA Pharmaceuticals has secured approval from its board of directors to acquire SKNY Pharmaceuticals, a company engaged in the development of SKNY-1 oral drug candidate for weight loss and smoking cessation.

Evotec secures $2.5m grant for TB treatment development

German life science company Evotec has been awarded a $2.5m grant from The Gates Foundation (GF) to enhance the development of tuberculosis (TB) treatment regimens.

FDA grants fast track status to Alterity’s multiple system atrophy treatment

The US Food and Drug Administration (FDA) has granted fast track designation to Alterity Therapeutics' oral agent ATH434 for treating multiple system atrophy (MSA).